Moore also believes that slower, more sustainable weight loss allows the body more time to adjust to changes in weight, reducing the side-effect profile and potentially leading to better long-term success
Just 2% of adults on Mississippi Medicaid who meet the weight-related criteria had been prescribed a GLP-1 as of December 2024, according to a report to the states Medicaid Drug Utilization Review Board
For a plain-language breakdown of why the two are combined, see our overview of the BPC-157 + TB-500 recovery blend explained, and browse related protocols in the full dosage catalog
Integrative Potential and Clinical Insight From a functional medicine perspective, GLP-1, GLP-2, and VIP peptides could become adjunctive supports in MCAS and related conditions such as IBS, POTS, EhlersDanlos syndrome, chronic fatigue, and long COVID, where mast-celldriven neuroinflammation plays a central role